TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Double Blind Study Comparing the Effect of Oropharyngeal Decontamination by Povidone-iodine to Placebo on Ventilator-associated Pneumonia in Patients With Head Trauma or Cerebral Hemorrhage
Brief Summary: Head trauma and severe cerebral hemorrhage are major risk factors for development of ventilator-associated pneumonia. In a previous open labelled, single center study the investigators showed that repeated oropharyngeal decontamination with povidone-iodine may be an effective strategy to decrease the prevalence of ventilator-associated pneumonia in patients with head trauma. The present study aims to confirm these results in a multicenter, double blind study including patients suffering from head trauma or cerebral hemorrhage.


Options:
A: Arm Label: povidone iodine; Type: EXPERIMENTAL; Interventions: Drug: povidone iodine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: povidone iodine; Assigned to Arm(s): povidone iodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: PROCEDURE; Name: Reinforced isolation + Muciprocine; Assigned to Arm(s): N/A
C: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine oral care (CHX-Oro), Drug: Selective oropharyngeal decontamination (SOD), Drug: Selective Digestive Decontamination (SDD) | Arm Label: Chlorhexidine oral care (CHX-Oro); Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine oral care (CHX-Oro) | Arm Label: Selective oropharyngeal decontamination; Type: EXPERIMENTAL; Interventions: Drug: Selective oropharyngeal decontamination (SOD) | Arm Label: Selective digestive decontamination; Type: EXPERIMENTAL; Interventions: Drug: Selective Digestive Decontamination (SDD) | Intervention Type: DRUG; Name: Chlorhexidine oral care (CHX-Oro); Assigned to Arm(s): Chlorhexidine oral care (CHX-Oro), Standard care | Intervention Type: DRUG; Name: Selective oropharyngeal decontamination (SOD); Assigned to Arm(s): Selective oropharyngeal decontamination, Standard care | Intervention Type: DRUG; Name: Selective Digestive Decontamination (SDD); Assigned to Arm(s): Selective digestive decontamination, Standard care
D: Arm Label: Arm 1: Usual Care-Active Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2: Targeted Decolonization; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine bath and nasal mupirocin | Arm Label: Arm 3: Universal Decolonization; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine bath and nasal mupirocin | Intervention Type: DRUG; Name: Chlorhexidine bath and nasal mupirocin; Assigned to Arm(s): Arm 2: Targeted Decolonization, Arm 3: Universal Decolonization

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Double Blind Study Comparing the Effect of Oropharyngeal Decontamination by Povidone-iodine to Placebo on Ventilator-associated Pneumonia in Patients With Head Trauma or Cerebral Hemorrhage
Brief Summary: Head trauma and severe cerebral hemorrhage are major risk factors for development of ventilator-associated pneumonia. In a previous open labelled, single center study the investigators showed that repeated oropharyngeal decontamination with povidone-iodine may be an effective strategy to decrease the prevalence of ventilator-associated pneumonia in patients with head trauma. The present study aims to confirm these results in a multicenter, double blind study including patients suffering from head trauma or cerebral hemorrhage.


Options:
A: Arm Label: povidone iodine; Type: EXPERIMENTAL; Interventions: Drug: povidone iodine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: povidone iodine; Assigned to Arm(s): povidone iodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: enhanced oral care; Type: EXPERIMENTAL; Interventions: Other: Enhanced Oral Care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual oral care | Intervention Type: OTHER; Name: Enhanced Oral Care; Assigned to Arm(s): enhanced oral care | Intervention Type: OTHER; Name: Usual oral care; Assigned to Arm(s): Usual care
C: Arm Label: Enhanced complex oral health care intervention; Type: EXPERIMENTAL; Interventions: Other: Enhanced complex oral health care | Arm Label: Usual oral health care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Enhanced complex oral health care; Assigned to Arm(s): Enhanced complex oral health care intervention
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Oral screen | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Oral screen; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Double Blind Study Comparing the Effect of Oropharyngeal Decontamination by Povidone-iodine to Placebo on Ventilator-associated Pneumonia in Patients With Head Trauma or Cerebral Hemorrhage
Brief Summary: Head trauma and severe cerebral hemorrhage are major risk factors for development of ventilator-associated pneumonia. In a previous open labelled, single center study the investigators showed that repeated oropharyngeal decontamination with povidone-iodine may be an effective strategy to decrease the prevalence of ventilator-associated pneumonia in patients with head trauma. The present study aims to confirm these results in a multicenter, double blind study including patients suffering from head trauma or cerebral hemorrhage.


Options:
A: Arm Label: povidone iodine; Type: EXPERIMENTAL; Interventions: Drug: povidone iodine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: povidone iodine; Assigned to Arm(s): povidone iodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Chlorhexidine gluconate (drug) vs placebo; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: oral hygiene | Intervention Type: OTHER; Name: oral hygiene; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 1
D: Arm Label: Biotene OralBalance® gel Arm; Type: EXPERIMENTAL; Interventions: Drug: Biotene OralBalance® gel | Arm Label: Sterile Water Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Sterile Water moisten cotton tipped applicator | Intervention Type: DRUG; Name: Biotene OralBalance® gel; Assigned to Arm(s): Biotene OralBalance® gel Arm | Intervention Type: OTHER; Name: Sterile Water moisten cotton tipped applicator; Assigned to Arm(s): Sterile Water Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Management for Improved Pregnancy Outcomes
Brief Summary: This study will examine the safety and effectiveness of a dietary intervention in pregnant women. Women who are obese will be invited to participate. The control arm will receive routine prenatal care and one in-person nutritional and dietary counseling session to promote healthy eating during their pregnancy. The intervention arm will receive a more intensive dietary program that will include in-person counseling and group support sessions. The goal of the intervention will be weight maintenance (weight at 2 weeks after delivery should be within 3% of baseline weight) and avoidance of postpartum weight retention


Options:
A: Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet and exercise counseling | Arm Label: Control, just measurements; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diet and exercise counseling; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: Enhanced Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard care | Arm Label: Intensive lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard care; Assigned to Arm(s): Enhanced Standard Care | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention
C: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Weight Management Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Management | Intervention Type: BEHAVIORAL; Name: Weight Management; Assigned to Arm(s): Weight Management Counseling | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Parents As Teachers + Lifestyle Int.; Type: EXPERIMENTAL; Interventions: Behavioral: Parents As Teachers Plus (PAT+) | Arm Label: Standard Parents as Teachers (PAT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Parents As Teachers (PAT) | Intervention Type: BEHAVIORAL; Name: Standard Parents As Teachers (PAT); Assigned to Arm(s): Standard Parents as Teachers (PAT) | Intervention Type: BEHAVIORAL; Name: Parents As Teachers Plus (PAT+); Assigned to Arm(s): Parents As Teachers + Lifestyle Int.

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Management for Improved Pregnancy Outcomes
Brief Summary: This study will examine the safety and effectiveness of a dietary intervention in pregnant women. Women who are obese will be invited to participate. The control arm will receive routine prenatal care and one in-person nutritional and dietary counseling session to promote healthy eating during their pregnancy. The intervention arm will receive a more intensive dietary program that will include in-person counseling and group support sessions. The goal of the intervention will be weight maintenance (weight at 2 weeks after delivery should be within 3% of baseline weight) and avoidance of postpartum weight retention


Options:
A: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Weight Management Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Management | Intervention Type: BEHAVIORAL; Name: Weight Management; Assigned to Arm(s): Weight Management Counseling | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Therapeutic education | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Follow-up | Intervention Type: OTHER; Name: Therapeutic education; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Follow-up; Assigned to Arm(s): 2
C: Arm Label: myo-inositol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: myo-inositol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: folic acid 400 mcg | Intervention Type: DIETARY_SUPPLEMENT; Name: myo-inositol; Assigned to Arm(s): myo-inositol | Intervention Type: OTHER; Name: folic acid 400 mcg; Assigned to Arm(s): placebo
D: Arm Label: Intensive Counseling Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary and lifestyle counseling | Arm Label: Routine care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary and lifestyle counseling; Assigned to Arm(s): Intensive Counseling Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Management for Improved Pregnancy Outcomes
Brief Summary: This study will examine the safety and effectiveness of a dietary intervention in pregnant women. Women who are obese will be invited to participate. The control arm will receive routine prenatal care and one in-person nutritional and dietary counseling session to promote healthy eating during their pregnancy. The intervention arm will receive a more intensive dietary program that will include in-person counseling and group support sessions. The goal of the intervention will be weight maintenance (weight at 2 weeks after delivery should be within 3% of baseline weight) and avoidance of postpartum weight retention


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low glycemic load | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Low glycemic load; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Supervised exercise for the prevention high weight gain; Assigned to Arm(s): N/A
C: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Weight Management Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Management | Intervention Type: BEHAVIORAL; Name: Weight Management; Assigned to Arm(s): Weight Management Counseling | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intramyocardial Transplantation of Bone Marrow Stem Cells for Improvement of Post-infarct Myocardial Regeneration in Addition to CABG Surgery: a Controlled, Prospective, Randomized, Double Blinded Multicenter Trial (PERFECT)
Brief Summary: In spite of the fact that the post-myocardial infarction survival rate has improved with recent medical advances, reduced heart function attributed to irreversible loss of viable cardiomyocytes is still a major clinical problem.

The aim of the current study is to determine whether intramyocardial injection of autologous CD133+ bone marrow stem cells yields a functional benefit in addition to coronary artery bypass graft (CABG) surgery in patients with chronic ischemic coronary artery disease.


Options:
A: Arm Label: Low-dose shock wave treatment & Placebo; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: low-dose shock-wave treatment & Cell therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: High-dose shock-wave treatment & Placebo; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: High-dose shock-wave treatment & cell therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: Placebo shock-wave treatment & cell therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Intervention Type: PROCEDURE; Name: intracoronary stem cell therapy; Assigned to Arm(s): High-dose shock-wave treatment & Placebo, High-dose shock-wave treatment & cell therapy, Low-dose shock wave treatment & Placebo, Placebo shock-wave treatment & cell therapy, low-dose shock-wave treatment & Cell therapy
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ranolazine placebo | Arm Label: Ranolazine; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Ranolazine placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Ranolazine | Intervention Type: DRUG; Name: Ranolazine placebo; Assigned to Arm(s): Placebo, Ranolazine
C: Arm Label: CD133+ autologous bone marrow stem cells; Type: ACTIVE_COMPARATOR; Interventions: Drug: CD133+ autologous bone marrow stem cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CD133+ autologous bone marrow stem cell; Assigned to Arm(s): CD133+ autologous bone marrow stem cells | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: C-Cure | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: C-Cure; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration
Brief Summary: This is a pilot interventional study whose aim is to determine the effect of a dietary supplementation with a Crocus Sativus extract, Saffron, on macular cone-mediated function in patients with early age-related macular degeneration (AMD). Pre-clinical evidence ( Maccarone R, Di Marco S, Bisti S. Saffron supplement maintains morphology and function after exposure to damaging light in mammalian retina. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1254-61.) indicates the potential effectiveness of Saffron as a retinal neuroprotectant in animal models of retinal degenerative disorders.The macular function will be tested by visual acuity and macular cone-mediated electroretinogram (focal electroretinogram, FERG) according to a standardized technique (see citations).


Options:
A: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Beta-Carotene; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin and mineral supplement, Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Intervention Type: DRUG; Name: vitamin and mineral supplement; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Escherichia coli Endotoxin (LPS); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 100% O2; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: nitroglycerin; Assigned to Arm(s): 1, 2
D: Arm Label: Saffron; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Saffron | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Saffron; Assigned to Arm(s): Saffron | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium). A Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study.
Brief Summary: In this phase III, multicenter study, 1200 patients with lung, breast, gastrointestinal (stomach, colon-rectum, pancreas), ovarian or head and neck cancer undergoing chemotherapy will be randomly assigned (at the beginning of cytotoxic therapy) in a 2:1 ratio and in double-blind conditions to a treatment with subcutaneous low molecular weight heparin (nadroparin calcium, one injection/day) or placebo for the overall duration of chemotherapy or up to a maximum of 4 months (+/- 10 days).


Options:
A: Arm Label: Intermittent Pneumatic Compression(IPC); Type: EXPERIMENTAL; Interventions: Device: pneumatic compression | Arm Label: No Intermittent Pneumatic Compression; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pneumatic compression; Assigned to Arm(s): Intermittent Pneumatic Compression(IPC)
B: Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Imatinib Mesylate; Assigned to Arm(s): N/A
C: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium). A Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study.
Brief Summary: In this phase III, multicenter study, 1200 patients with lung, breast, gastrointestinal (stomach, colon-rectum, pancreas), ovarian or head and neck cancer undergoing chemotherapy will be randomly assigned (at the beginning of cytotoxic therapy) in a 2:1 ratio and in double-blind conditions to a treatment with subcutaneous low molecular weight heparin (nadroparin calcium, one injection/day) or placebo for the overall duration of chemotherapy or up to a maximum of 4 months (+/- 10 days).


Options:
A: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin + docetaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: cisplatin + docetaxel + enoxaparin | Intervention Type: DRUG; Name: cisplatin + docetaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin + docetaxel + enoxaparin; Assigned to Arm(s): Arm B
B: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution
C: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drug | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo drug; Assigned to Arm(s): Placebo drug
D: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy at the investigator's discretion | Arm Label: dalteparin; Type: EXPERIMENTAL; Interventions: Drug: daltéparine, Drug: Chemotherapy at the investigator's discretion | Intervention Type: DRUG; Name: daltéparine; Assigned to Arm(s): dalteparin | Intervention Type: DRUG; Name: Chemotherapy at the investigator's discretion; Assigned to Arm(s): chemotherapy, dalteparin

Answer: B